Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Consideration of Drug Therapy in Benign Prostatic Hypertrophy

Consideration of Drug Therapy in Benign Prostatic Hypertrophy ARS Medica Tomitana - 2014; 3(78): 129 - 134 10.2478/arsm-2014-0023 Diamantis G., Tode V. Doctoral School of Medicine, University “Ovidius” Constanta, Romania ABSTRACT Introduction Benign prostatic hypertrophy (BPH) has become a major global health problem both in its frequency by which it determines the complications and the problems of diagnosis and treatment it requires. BPH Clinical research in this study is mainly aimed is a heterogeneous disease. The symptoms attributed to BPH may have other coexisting causes and growth at studying the effectiveness of non invasive treatment factors both androgen-dependent and independent, of prostate adenoma were used as methods of therapy which promotes prostate enlargement. It is well known drug therapy (alpha-blockers, 5a-reductase inhibitors, that prostate size correlates poorly with the symptoms combination therapy) and active surveillance of so that reducing prostate using 5-alphareductase or patients suffering from this condition. For efficiency alphablocants inhibitors may not always be sufficient. and purposefulness main monitor and set the weight of A better understanding of the pathophysiology of each type of non-invasive treatment and medication, BPH and its interactions with other drugs will help the performing correlations between patient age and the development of new substances with a better efficiency. treatment used. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ARS Medica Tomitana de Gruyter

Consideration of Drug Therapy in Benign Prostatic Hypertrophy

ARS Medica Tomitana , Volume 20 (3) – Jan 31, 2015

Loading next page...
 
/lp/de-gruyter/consideration-of-drug-therapy-in-benign-prostatic-hypertrophy-rIlA0hRxze
Publisher
de Gruyter
Copyright
Sciendo is a De Gruyter company © 2018. ALL RIGHTS RESERVED Powered by PubFactory
ISSN
1841-4036
DOI
10.2478/arsm-2014-0023
Publisher site
See Article on Publisher Site

Abstract

ARS Medica Tomitana - 2014; 3(78): 129 - 134 10.2478/arsm-2014-0023 Diamantis G., Tode V. Doctoral School of Medicine, University “Ovidius” Constanta, Romania ABSTRACT Introduction Benign prostatic hypertrophy (BPH) has become a major global health problem both in its frequency by which it determines the complications and the problems of diagnosis and treatment it requires. BPH Clinical research in this study is mainly aimed is a heterogeneous disease. The symptoms attributed to BPH may have other coexisting causes and growth at studying the effectiveness of non invasive treatment factors both androgen-dependent and independent, of prostate adenoma were used as methods of therapy which promotes prostate enlargement. It is well known drug therapy (alpha-blockers, 5a-reductase inhibitors, that prostate size correlates poorly with the symptoms combination therapy) and active surveillance of so that reducing prostate using 5-alphareductase or patients suffering from this condition. For efficiency alphablocants inhibitors may not always be sufficient. and purposefulness main monitor and set the weight of A better understanding of the pathophysiology of each type of non-invasive treatment and medication, BPH and its interactions with other drugs will help the performing correlations between patient age and the development of new substances with a better efficiency. treatment used.

Journal

ARS Medica Tomitanade Gruyter

Published: Jan 31, 2015

Keywords: Medicine; Clinical Medicine; Clinical Medicine, other

References